Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding the Recording of Non-Operating Income (Grant income)
Corporate Governance Report
(Delayed)Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2025
Announcement on the Reduction of Capital Reserve and Appropriation of Surplus
Publication of Research on the Discovery of CLK Inhibitor Rogocekib (Follow-up announcement)
Fiscal year ended August 2025 Financial Results Presentation
Chordia Therapeutics, The Current Fiscal Year's Net Income to Widen
Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances
Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2025 [Japanese GAAP]
Notice regarding the Publication of the Revised Clinical Trial Protocol Summary for rogocekib
Publication of Research on the Discovery of CLK Inhibitor Rogocekib
Notice of Commencement of Joint Research with Senju Pharmaceutical Co., Ltd.
Chordia Therapeutics, Sep-May (Cumulative 3Q) Net Income Loss Widens, Mar-May Net Income Loss Widens
Non-consolidated Financial Results for the Nine Months Ended May 31, 2025 [Japanese GAAP]
Notice of Commencement of Joint Research with D. Western Therapeutics Institute, Inc.
Notice of Receipt of Grant
Notice Concerning Change of Major Shareholder
Notice of Discontinuation of Development of CTX-177 (ONO-7018)
Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025
Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025